Jan Heckelmann

Dr. Jan Heckelmann

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Klinische Neurophysiologie
Verified
Journal Article
Closed access
PDF file
JHJan Heckelmann
Jan Heckelmann
YWYvonne Weber
Yvonne Weber
Eine Vielzahl von Präparaten mit Einfluss auf das zentrale Nervensystem, insbesondere Medikamente, die zur Standard-Therapie auf neurologischen Intensiv- und Überwachungsstationen gehören, haben einen Einfluss auf den elektroenzephalograhischen (EEG) Befund. Diese Effekte reichen von geringen Einflüssen auf Grundrhythmus und EEG-Amplituden bis zur Auslösung von epileptiformer Aktivität und Anfallsmustern. Kenntnisse über die zu erwartenden Veränderungen sind daher relevant, um neben krankheitsassoziierten Auffälligkeiten im Rahmen der Differentialdiagnostik auch medikamentöse Ursachen bedenken zu können und etwaige therapeutische Konsequenzen einzuleiten. In dem vorliegenden Übersichtartikel werden neben Einflüssen von Analgosedierung und antikonvulsiven Medikamenten auch Effekte von Neuroleptika, Antidepressiva, Immunsuppressiva sowie Antibiotika auf das EEG diskutiert. A large number of drugs active at the central nervous system, especially drugs that are part of the standard therapy in neurological intensive care units and monitoring wards, influence the electroencephalography (EEG). These effects range from minor influences on the basic rhythm and amplitudes to epileptiform activity and seizures. Thus, the knowledge of the changes to be expected is relevant in order to be able to also take drug-related causes into account besides disease-associated abnormalities in the course of differential diagnosis and to be able to evaluate therapeutic consequences. In addition to the EEG changes caused by analgesic sedation and anticonvulsants, the present review article also describes the influence of neuroleptic and antidepressant medication, immunosuppressants and antibiotics hereunto. Article published online: 07 September 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

2 September 2026 in Toxins
Verified
Journal Article
Open access
PDF file
SPSebastian Paus
Sebastian Paus
AFAndreas Funke
Andreas Funke
JHJürgen Hamacher
Jürgen Hamacher
BHBernhard Haslinger
Bernhard Haslinger
JHJan Heckelmann
Jan Heckelmann
DWDavid Weise
David Weise
Cervical dystonia (CD) is a hyperkinetic movement disorder characterized by involuntary muscle contractions leading to abnormal postures of the head and neck. The injection of botulinum neurotoxin type A (BoNT-A) into the muscles involved is the treatment of choice for CD. BoNT-A therapy of CD requires appropriate training, which has not been standardized in Germany. To address the key challenges in BoNT-A education, an expert panel developed a simplified step-by-step treatment guideline for beginners, adapted from the established Col-Cap-Concept (“Dystonia 3×3”). Based on expert consensus, recommendations were developed for the core clinical elements of BoNT-A treatment in CD—recognition of the movement pattern, identification of target muscles, development of an injection plan, ultrasound-guided injection, and dosing, taking into account the target audience of the guideline. As such, Dystonia 3×3 provides a user-friendly beginner’s guidebook, enhancing accessibility and standardization of CD treatment training. Further research is required to evaluate its clinical efficacy and suitability for training.

27 November 2024
Verified
Book Chapter
Closed access
PDF file
JHJan Heckelmann
Jan Heckelmann
YWYvonne Weber
Yvonne Weber